Alcresta is developing and commercializing innovative enzyme-based nutritional products that improve patient health and manage disease for infants, adults and patients battling acute or chronic conditions. The demand for high-value nutritional products is increasing, driving the growth of a $33 billion global market. While there have been important recent advances in supplemented nutritional products, there remains a significant need for enzyme-based nutritional products that support healthier living and complement conventional medical care.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/17/12 | $10,000,000 | Series A |
Frazier Healthcare Third Rock Ventures | undisclosed |
| 07/22/13 | $10,000,000 | Series B |
Frazier Healthcare Third Rock Ventures | undisclosed |
